Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Debt: 2021-2024

  • Abivax's Total Debt rose 46.96% to $121.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $121.8 million, marking a year-over-year increase of 46.96%. This contributed to the annual value of $121.8 million for FY2024, which is 46.96% up from last year.
  • Abivax's Total Debt amounted to $121.8 million in Q4 2024, which was up 46.96% from $82.9 million recorded in Q4 2023.
  • Abivax's Total Debt's 5-year high stood at $121.8 million during Q4 2024, with a 5-year trough of $13.0 million in Q4 2021.
  • In the last 3 years, Abivax's Total Debt had a median value of $82.9 million in 2023 and averaged $85.2 million.
  • Data for Abivax's Total Debt shows a peak YoY skyrocketed of 291.45% (in 2022) over the last 5 years.
  • Over the past 4 years, Abivax's Total Debt (Quarterly) stood at $13.0 million in 2021, then skyrocketed by 291.45% to $50.8 million in 2022, then skyrocketed by 63.17% to $82.9 million in 2023, then soared by 46.96% to $121.8 million in 2024.
  • Its last three reported values are $121.8 million in Q4 2024, $82.9 million for Q4 2023, and $50.8 million during Q4 2022.